[Form 4] Savara Inc Insider Trading Activity

Rhea-AI Filing Summary

Savara Inc. (SVRA) Form 4: The company’s Chief Medical Officer reported equity awards on 10/20/2025. The filing shows an acquisition of 35,000 restricted stock units (RSUs) at a price of $0.00, lifting directly held common shares to 190,000 following the transaction. The RSUs vest in full on 10/17/2027, each converting into one share upon vesting.

Separately, the officer received a stock option for 70,000 shares with an exercise price of $4.11 and an expiration on 10/20/2035. This option vests in sixteen equal quarterly installments beginning 10/17/2025. These are routine compensatory awards and do not indicate open‑market buying or selling.

Insights

Equity Compensation Analyst

Routine equity grants; neutral impact.

Savara's CMO received standard compensation awards: 35,000 RSUs that cliff-vest on 10/17/2027 and a 70,000-share option at $4.11 expiring 10/20/2035. The RSUs were recorded at $0.00 as is typical for awards.

Form 4 indicates these are grants, not open‑market purchases or sales. Any dilution effect would depend on future vesting and exercises, as permitted by the schedules disclosed.

The filing also notes total common stock beneficially owned at 190,000 after the RSU grant. Subsequent filings may provide additional updates on vesting or exercises as they occur.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wasfi Yasmine

(Last) (First) (Middle)

ONE SUMMIT SQUARE,

1717 LANGHORNE NEWTOWN ROAD, SUITE 300

(Street)

LANGHORNE PA 19047

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Savara Inc [ SVRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/20/2025	10/20/2025	A		35,000(1)	A	$0.00	190,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.11	10/20/2025	10/20/2025	A		70,000		(2)	10/20/2035	Common Stock	70,000	$0.00	70,000	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs") that vest in full on October 17, 2027, subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

2. The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of October 17, 2025, subject to the reporting person's continued service with the Issuer.

	/s/ Kate McCabe as attorney-in-fact for Yasmine Wasfi	10/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.